DZ2880A1 - Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant. - Google Patents

Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.

Info

Publication number: DZ2880A1
Authority: DZ; Algeria
Prior art keywords: alkynyl; derivatives; preparation; pharmaceutical compositions; compositions containing
Prior art date: 1998-08-27

Application number

DZ990180A

Other languages

English (en)

Inventor

La Susan Deborah Crega

Joseph Peter Lyssikatos

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-25

Publication date

2003-12-15

1999-08-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2880A1 publication Critical patent/DZ2880A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DZ990180A 1998-08-27 1999-08-25 Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant. DZ2880A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9814598P	1998-08-27	1998-08-27

Publications (1)

Publication Number	Publication Date
DZ2880A1 true DZ2880A1 (fr)	2003-12-15

Family

ID=22267481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990180A DZ2880A1 (fr)	1998-08-27	1999-08-25	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.

Country Status (40)

Country	Link
US (3)	US6150377A (fr)
EP (1)	EP1107963B1 (fr)
JP (1)	JP3495706B2 (fr)
KR (1)	KR20010072991A (fr)
CN (1)	CN1314904A (fr)
AP (1)	AP2001002079A0 (fr)
AT (1)	ATE321037T1 (fr)
AU (1)	AU4925499A (fr)
BG (1)	BG105365A (fr)
BR (1)	BRPI9913138B8 (fr)
CA (2)	CA2578326C (fr)
CO (1)	CO5130017A1 (fr)
CZ (1)	CZ2001660A3 (fr)
DE (1)	DE69930518T2 (fr)
DZ (1)	DZ2880A1 (fr)
EA (1)	EA200100135A1 (fr)
EE (1)	EE200100118A (fr)
ES (1)	ES2259237T3 (fr)
GE (1)	GEP20033001B (fr)
GT (1)	GT199900140A (fr)
HK (1)	HK1039123A1 (fr)
HR (1)	HRP20010142A2 (fr)
HU (1)	HUP0103228A3 (fr)
ID (1)	ID27562A (fr)
IL (1)	IL141239A0 (fr)
IS (1)	IS5818A (fr)
MA (1)	MA26680A1 (fr)
NO (1)	NO20010964L (fr)
NZ (1)	NZ509372A (fr)
OA (1)	OA11645A (fr)
PA (1)	PA8480101A1 (fr)
PE (1)	PE20000986A1 (fr)
PL (1)	PL346426A1 (fr)
SK (1)	SK2442001A3 (fr)
SV (1)	SV1999000141A (fr)
TN (1)	TNSN99162A1 (fr)
TR (1)	TR200101343T2 (fr)
UY (1)	UY25682A1 (fr)
WO (1)	WO2000012499A1 (fr)
ZA (1)	ZA200101173B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
HRP20000904A2 (en) *	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
HUP0103228A3 (en) *	1998-08-27	2003-01-28	Pfizer Prod Inc	Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents and pharmaceutical compositions containing them
WO2000012498A1 (fr) *	1998-08-27	2000-03-09	Pfizer Products Inc.	Derives de quinolin-2-one utiles en tant qu'agents anticancereux
CN1340051A (zh)	1999-02-11	2002-03-13	辉瑞产品公司	可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
HN2000000266A (es)	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
AU2001231763A1 (en)	2000-02-24	2001-09-03	Janssen Pharmaceutica N.V.	Dosing regimen
JO2361B1 (en) *	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
JP4974437B2 (ja)	2000-09-25	2012-07-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
US7196094B2 (en)	2000-09-25	2007-03-27	Janssen Pharmaceutica, N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
WO2002024687A1 (fr) *	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Derives de 6-heterocyclylmethyl quinolinone inhibant la farnesyl transferase
DE60118225T2 (de)	2000-09-25	2007-05-03	Janssen Pharmaceutica N.V.	Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU2002214056A1 (en)	2000-11-21	2002-06-03	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting benzoheterocyclic derivatives
JP2004516287A (ja)	2000-12-19	2004-06-03	ファイザー・プロダクツ・インク	６−［（４−クロロ−フェニル）−ヒドロキシ−（３−メチル−３ｈ−イミダゾール−４−イル）−メチル］−４−（３−エチニル−フェニル）−１−メチル−１ｈ−キノリン−２−オン，２，３−ジヒドロキシブタン二酸塩の結晶形および製造方法
ES2260316T3 (es) *	2000-12-27	2006-11-01	Janssen Pharmaceutica N.V.	Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
AU2002236813A1 (en) *	2001-01-22	2002-07-30	Schering Corporation	Treatment of malaria with farnesyl protein transferase inhibitors
ES2236505T3 (es) *	2001-03-12	2005-07-16	Janssen Pharmaceutica N.V.	Procedimiento para la preparacin de compuestos de imidazol.
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
WO2002080895A2 (fr) *	2001-04-06	2002-10-17	Schering Corporation	Traitements antipaludiques comprenant l'administration d'inhibiteurs de la fasnesyl proteine transferase
WO2002098425A1 (fr) *	2001-06-04	2002-12-12	Cytovia, Inc.	Quinolinones 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)- substituees, et analogues utilises comme activateurs de caspases et inducteurs d'apoptose, et utilisation y relative
US6713462B2 (en)	2001-06-21	2004-03-30	Ariad Pharmaceuticals, Inc.	Quinolinones and uses thereof
US6740757B2 (en) *	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
DE60231646D1 (de)	2001-12-19	2009-04-30	Janssen Pharmaceutica Nv	Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
WO2003080058A1 (fr)	2002-03-22	2003-10-02	Janssen Pharmaceutica. N.V.	Derives de 2-quinoleine et de 2-quinazoline substitues par du benzylimidazole utilises en tant qu'inhibiteurs de farnesyl transferase
ATE336496T1 (de)	2002-04-15	2006-09-15	Janssen Pharmaceutica Nv	Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
RS20050430A (sr) *	2002-12-19	2007-08-03	Pfizer Inc.,	Jedinjenja 2-(1h-indazol-6-ilamino)- benzamida kao inhibitori protein kinaza, korisni u tretmanu oftalmoloških bolesti
WO2005051392A1 (fr)	2003-11-20	2005-06-09	Children's Hospital Medical Center	Inhibiteurs de gtpase et procedes d'utilisation correspondants
WO2005089515A2 (fr) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Procedes de traitement des synucleinopathies
WO2005094830A1 (fr) *	2004-03-30	2005-10-13	Pfizer Products Inc.	Combinaisons d'inhibiteurs de transduction de signaux
JP2008510792A (ja) *	2004-08-26	2008-04-10	ファイザー・インク	タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
EP1784396B8 (fr) *	2004-08-26	2011-04-20	Pfizer Inc.	Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase
PT1786785E (pt) *	2004-08-26	2010-05-21	Pfizer	Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase
US20060111398A1 (en)	2004-11-05	2006-05-25	Fourie Anne M	Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof
US20060107555A1 (en) *	2004-11-09	2006-05-25	Curtis Marc D	Universal snow plow adapter
US20060281788A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006275528B2 (en)	2005-07-29	2012-03-08	Children's Hospital Medical Center	GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
SI1933871T1 (sl)	2005-09-07	2013-10-30	Amgen Fremont Inc.	Humana monoklonska protitelesa proti aktivin receptorju podobni kinazi-1
DK1926996T3 (da)	2005-09-20	2012-01-23	Osi Pharmaceuticals Llc	Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
WO2007075923A2 (fr)	2005-12-23	2007-07-05	Link Medicine Corporation	Traitement de formes de synucleinopathie
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP5089681B2 (ja)	2006-04-20	2012-12-05	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ｃ−ｆｍｓキナーゼの阻害剤としての複素環式化合物
CA2650057C (fr)	2006-04-20	2014-07-29	Janssen Pharmaceutica N.V.	Phenylamides ou pyridinylamides en tant qu'inhibiteurs de la kinase du c-fms
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
EP2021338A1 (fr)	2006-05-09	2009-02-11	Pfizer Products Inc.	Dérivés d'acide cycloalkylaminé et compositions pharmaceutiques à base de ceux-ci
SI2056874T1 (sl)	2006-08-21	2012-12-31	F. Hoffmann-La Roche Ag	Terapija tumorjev s protitelesom proti vegf
WO2008112525A2 (fr) *	2007-03-09	2008-09-18	Link Medicine Corporation	Traitement des maladies de surcharge lysosomale
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
WO2009151683A2 (fr)	2008-03-12	2009-12-17	Link Medicine Corporation	Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
DE102008022221A1 (de) *	2008-05-06	2009-11-12	Universität des Saarlandes	Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010057006A1 (fr)	2008-11-13	2010-05-20	Link Medicine Corporation	Dérivés d'azaquinolinone et leurs applications
EP2400985A2 (fr)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Thérapie anti-cancer combinée
EP2400990A2 (fr)	2009-02-26	2012-01-04	OSI Pharmaceuticals, LLC	Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
CA2783665A1 (fr)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Marqueurs biologiques predictifs d'une reponse anticancereuse aux inhibiteurs de kinase du recepteur du facteur de croissance insulinique 1
US20110275644A1 (en)	2010-03-03	2011-11-10	Buck Elizabeth A	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en)	2011-02-22	2012-08-23	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (fr)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
WO2013166043A1 (fr)	2012-05-02	2013-11-07	Children's Hospital Medical Center	Rajeunissement de cellules précurseurs
JOP20180012A1 (ar)	2012-08-07	2019-01-30	Janssen Pharmaceutica Nv	عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (fr)	2012-08-07	2016-10-05	Janssen Pharmaceutica, N.V.	Procédé pour la préparation de dérivés d'ester hétérocyclique
AR094403A1 (es)	2013-01-11	2015-07-29	Hoffmann La Roche	Terapia de combinación de anticuerpos anti-her3
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
RS62709B1 (sr)	2015-08-17	2022-01-31	Kura Oncology Inc	Postupci za lečenje pacijenata obolelih od kancera pomoću inhibitora farneziltransferaze
WO2017096165A1 (fr)	2015-12-03	2017-06-08	Agios Pharmaceuticals, Inc.	Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
US20190119758A1 (en)	2016-04-22	2019-04-25	Kura Oncology, Inc.	Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
PL3534885T3 (pl)	2016-11-03	2021-11-15	Kura Oncology, Inc.	Inhibitory farnezylotransferazy do zastosowania w leczeniu nowotworu
EP3579872A1 (fr)	2017-02-10	2019-12-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
US10137121B2 (en)	2017-02-21	2018-11-27	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2018156609A1 (fr)	2017-02-21	2018-08-30	Kura Oncology, Inc.	Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
WO2019032489A1 (fr)	2017-08-07	2019-02-14	Kura Oncology, Inc.	Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (fr)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
WO2020092720A2 (fr)	2018-11-01	2020-05-07	Kura Oncology, Inc.	Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
KR20210106513A (ko)	2018-12-21	2021-08-30	쿠라 온콜로지, 인크.	편평 세포 암종을 위한 요법
US20220142983A1 (en)	2019-03-01	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
TW202108170A (zh)	2019-03-15	2021-03-01	美商庫拉腫瘤技術股份有限公司	以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
KR20210144778A (ko)	2019-03-29	2021-11-30	쿠라 온콜로지, 인크.	파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
TW202102218A (zh)	2019-04-01	2021-01-16	美商庫拉腫瘤技術股份有限公司	以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
WO2020223583A1 (fr)	2019-05-02	2020-11-05	Kura Oncology, Inc.	Méthodes de traitement de la leucémie myéloïde aiguë avec des inhibiteurs de la farnésyltransférase
EP4013402B1 (fr)	2019-08-16	2024-11-06	Children's Hospital Medical Center	Inhibiteurs de cdc42 pour utilisation dans le traitement de la dépression, de la sarcopénie ou de la fragilité associées à l'âge
WO2021155006A1 (fr)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
BR9610745A (pt) *	1995-12-08	1999-07-13	Janssen Pharmaceutica Nv	Derivados de (imidazol-5-il) metil-2-quinolinona inibindo a transferase da proteina farnesil
HUP0103228A3 (en) *	1998-08-27	2003-01-28	Pfizer Prod Inc	Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents and pharmaceutical compositions containing them

1999
- 1999-08-06 HU HU0103228A patent/HUP0103228A3/hu unknown
- 1999-08-06 SK SK244-2001A patent/SK2442001A3/sk unknown
- 1999-08-06 NZ NZ509372A patent/NZ509372A/en unknown
- 1999-08-06 AP APAP/P/2001/002079A patent/AP2001002079A0/en unknown
- 1999-08-06 EP EP99933084A patent/EP1107963B1/fr not_active Expired - Lifetime
- 1999-08-06 CN CN99810204A patent/CN1314904A/zh active Pending
- 1999-08-06 HR HR20010142A patent/HRP20010142A2/hr not_active Application Discontinuation
- 1999-08-06 ID IDW20010457A patent/ID27562A/id unknown
- 1999-08-06 JP JP2000567527A patent/JP3495706B2/ja not_active Expired - Fee Related
- 1999-08-06 WO PCT/IB1999/001398 patent/WO2000012499A1/fr not_active Ceased
- 1999-08-06 ES ES99933084T patent/ES2259237T3/es not_active Expired - Lifetime
- 1999-08-06 AU AU49254/99A patent/AU4925499A/en not_active Abandoned
- 1999-08-06 OA OA1200100051A patent/OA11645A/en unknown
- 1999-08-06 EA EA200100135A patent/EA200100135A1/ru unknown
- 1999-08-06 BR BRPI9913138A patent/BRPI9913138B8/pt not_active IP Right Cessation
- 1999-08-06 KR KR1020017002442A patent/KR20010072991A/ko not_active Ceased
- 1999-08-06 EE EEP200100118A patent/EE200100118A/xx unknown
- 1999-08-06 GE GEAP19995770A patent/GEP20033001B/en unknown
- 1999-08-06 CA CA002578326A patent/CA2578326C/fr not_active Expired - Fee Related
- 1999-08-06 CZ CZ2001660A patent/CZ2001660A3/cs unknown
- 1999-08-06 DE DE69930518T patent/DE69930518T2/de not_active Expired - Lifetime
- 1999-08-06 CA CA002341690A patent/CA2341690C/fr not_active Expired - Fee Related
- 1999-08-06 PL PL99346426A patent/PL346426A1/xx not_active Application Discontinuation
- 1999-08-06 AT AT99933084T patent/ATE321037T1/de not_active IP Right Cessation
- 1999-08-06 IL IL14123999A patent/IL141239A0/xx unknown
- 1999-08-06 HK HK02100579.7A patent/HK1039123A1/zh unknown
- 1999-08-06 TR TR2001/01343T patent/TR200101343T2/xx unknown
- 1999-08-10 PA PA19998480101A patent/PA8480101A1/es unknown
- 1999-08-24 GT GT199900140A patent/GT199900140A/es unknown
- 1999-08-25 DZ DZ990180A patent/DZ2880A1/fr active
- 1999-08-25 TN TNTNSN99162A patent/TNSN99162A1/fr unknown
- 1999-08-25 MA MA25743A patent/MA26680A1/fr unknown
- 1999-08-26 US US09/383,755 patent/US6150377A/en not_active Expired - Lifetime
- 1999-08-26 PE PE1999000862A patent/PE20000986A1/es not_active Application Discontinuation
- 1999-08-27 UY UY25682A patent/UY25682A1/es unknown
- 1999-08-27 SV SV1999000141A patent/SV1999000141A/es not_active Application Discontinuation
- 1999-08-27 CO CO99054519A patent/CO5130017A1/es unknown
2000
- 2000-07-27 US US09/628,039 patent/US6294552B1/en not_active Expired - Lifetime
2001
- 2001-01-19 IS IS5818A patent/IS5818A/is unknown
- 2001-02-12 ZA ZA200101173A patent/ZA200101173B/en unknown
- 2001-02-26 NO NO20010964A patent/NO20010964L/no not_active Application Discontinuation
- 2001-03-20 BG BG105365A patent/BG105365A/xx unknown
- 2001-07-06 US US09/900,401 patent/US6579887B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6294552B1 (en)	2001-09-25
TR200101343T2 (tr)	2001-09-21
JP3495706B2 (ja)	2004-02-09
PE20000986A1 (es)	2000-09-30
AU4925499A (en)	2000-03-21
BRPI9913138B8 (pt)	2016-05-17
WO2000012499A1 (fr)	2000-03-09
BR9913138B1 (pt)	2013-11-05
NO20010964D0 (no)	2001-02-26
KR20010072991A (ko)	2001-07-31
HK1039123A1 (zh)	2002-04-12
SV1999000141A (es)	2000-07-06
ZA200101173B (en)	2002-04-12
CN1314904A (zh)	2001-09-26
IS5818A (is)	2001-01-19
GT199900140A (es)	2001-02-14
UY25682A1 (es)	2000-03-31
CZ2001660A3 (cs)	2002-05-15
US20020128287A1 (en)	2002-09-12
US6579887B2 (en)	2003-06-17
IL141239A0 (en)	2002-03-10
EP1107963B1 (fr)	2006-03-22
EE200100118A (et)	2002-06-17
MA26680A1 (fr)	2004-12-20
EA200100135A1 (ru)	2001-08-27
JP2002523504A (ja)	2002-07-30
GEP20033001B (en)	2003-06-25
OA11645A (en)	2004-11-16
CO5130017A1 (es)	2002-02-27
DE69930518T2 (de)	2006-09-21
BR9913138A (pt)	2001-05-08
BG105365A (en)	2001-11-30
ES2259237T3 (es)	2006-09-16
PL346426A1 (en)	2002-02-11
AP2001002079A0 (en)	2001-03-31
PA8480101A1 (es)	2003-06-30
HUP0103228A2 (hu)	2002-02-28
ATE321037T1 (de)	2006-04-15
ID27562A (id)	2001-04-12
HUP0103228A3 (en)	2003-01-28
SK2442001A3 (en)	2002-10-08
CA2578326C (fr)	2009-11-24
CA2341690C (fr)	2007-04-17
US6150377A (en)	2000-11-21
CA2578326A1 (fr)	2000-03-09
NZ509372A (en)	2003-08-29
HRP20010142A2 (en)	2002-02-28
TNSN99162A1 (fr)	2005-11-10
CA2341690A1 (fr)	2000-03-09
NO20010964L (no)	2001-04-26
EP1107963A1 (fr)	2001-06-20
DE69930518D1 (de)	2006-05-11

Publication	Publication Date	Title
DZ2880A1 (fr)	2003-12-15	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr)	2004-03-27	Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2708608B1 (fr)	1995-10-27	Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
DZ2407A1 (fr)	2003-01-04	Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2708606B1 (fr)	1995-10-27	Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2188A1 (fr)	2002-12-02	Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CH689805A8 (fr)	2000-02-29	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.